Phreesia (NYSE:PHR) Expected to Announce Earnings of -$0.10 Per Share

Equities analysts expect Phreesia (NYSE:PHR) to announce earnings per share (EPS) of ($0.10) for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Phreesia’s earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.09). The firm is scheduled to issue its next earnings report on Monday, December 9th.

According to Zacks, analysts expect that Phreesia will report full-year earnings of ($0.50) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.40). For the next year, analysts expect that the business will post earnings of ($0.34) per share, with EPS estimates ranging from ($0.41) to ($0.24). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Phreesia.

Phreesia (NYSE:PHR) last announced its earnings results on Tuesday, December 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.80 million during the quarter, compared to analyst estimates of $29.48 million. Phreesia’s revenue was up 32.3% on a year-over-year basis.

Several brokerages have recently weighed in on PHR. Robert W. Baird initiated coverage on shares of Phreesia in a research note on Thursday, October 10th. They set an “outperform” rating and a $31.00 price target for the company. Zacks Investment Research lowered shares of Phreesia from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. started coverage on shares of Phreesia in a report on Tuesday, August 13th. They set an “overweight” rating and a $33.00 target price for the company. ValuEngine downgraded shares of Phreesia from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Finally, Piper Jaffray Companies set a $33.00 target price on shares of Phreesia and gave the company a “buy” rating in a research report on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Phreesia presently has a consensus rating of “Buy” and a consensus target price of $30.60.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. TimesSquare Capital Management LLC acquired a new position in shares of Phreesia during the 3rd quarter worth approximately $29,435,000. Massachusetts Financial Services Co. MA bought a new position in shares of Phreesia in the third quarter valued at $11,955,000. Tamarack Advisers LP bought a new position in shares of Phreesia in the third quarter valued at $4,848,000. State Street Corp acquired a new position in Phreesia during the third quarter worth $3,827,000. Finally, Emerald Advisers LLC acquired a new position in Phreesia during the third quarter worth $1,036,000. 49.88% of the stock is owned by hedge funds and other institutional investors.

NYSE:PHR opened at $28.83 on Friday. Phreesia has a twelve month low of $22.05 and a twelve month high of $31.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.52 and a quick ratio of 3.52. The business’s 50 day moving average price is $28.73.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Read More: Balanced Fund

Get a free copy of the Zacks research report on Phreesia (PHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.